Serina Therapeutics Total Debt Growth & History (SER)
Serina Therapeutics's total debt was $3.3M for fiscal 2025.
View full Serina Therapeutics company overviewSerina Therapeutics annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.3M | $2.9M | +620.82% |
| 2024 | 2024-12-31 | $461,000 | −$3.2M | −87.52% |
| 2023 | 2023-12-31 | $3.7M | −$14.4M | −79.61% |
| 2022 | 2022-12-31 | $18.1M | $4.9M | +37.28% |
| 2021 | 2021-12-31 | $13.2M | — | — |
| 2019 | 2019-12-31 | $428,000 | — | — |
Serina Therapeutics quarterly total debt
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.2M | $2.8M | +786.46% |
| Q1 2026 | 2026-03-31 | $3.3M | $2.9M | +709.95% |
| Q4 2025 | 2025-12-31 | $3.3M | $2.9M | +620.82% |
| Q3 2025 | 2025-09-30 | $311,000 | −$199,000 | −39.02% |
| Q2 2025 | 2025-06-30 | $362,000 | −$211,000 | −36.82% |
| Q1 2025 | 2025-03-31 | $412,000 | −$232,000 | −36.02% |
| Q4 2024 | 2024-12-31 | $461,000 | −$3.2M | −87.52% |
| Q3 2024 | 2024-09-30 | $510,000 | — | — |
| Q2 2024 | 2024-06-30 | $573,000 | — | — |
| Q1 2024 | 2024-03-31 | $644,000 | — | — |
| Q4 2023 | 2023-12-31 | $3.7M | −$14.4M | −79.61% |
| Q4 2022 | 2022-12-31 | $18.1M | $4.9M | +37.28% |
| Q3 2022 | 2022-09-30 | $15.6M | — | — |
| Q4 2021 | 2021-12-31 | $13.2M | — | — |
| Q3 2020 | 2020-09-30 | $109,000 | −$420,000 | −79.40% |
| Q2 2020 | 2020-06-30 | $218,000 | −$631,000 | −74.32% |
| Q1 2020 | 2020-03-31 | $325,000 | — | — |
| Q4 2019 | 2019-12-31 | $428,000 | — | — |
| Q3 2019 | 2019-09-30 | $529,000 | — | — |
| Q2 2019 | 2019-06-30 | $849,000 | — | — |
Serina Therapeutics total debt trends
Between the periods ended 2019-12-31 and 2025-12-31, Serina Therapeutics's total debt increased from $428,000 to $3.3M, a change of $2.9M. The latest reported quarter, Q2 2026, shows $3.2M.
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Serina Therapeutics source filings ↗